文献速递头颈外科

FDG PET-CT 用于口咽癌复发检测的准确性:手术与放化疗比较

Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2018-01-01

该回顾性队列研究纳入190例接受根治性治疗的口咽鳞癌患者,比较治疗后初始 FDG PET-CT 在手术与放化疗两组间的诊断准确性,并探索假阳性指标。结果显示手术组 PPV 高于放化疗组,NPV 均很高,SUVmax 最佳截断值手术组为5.1、放化疗组为5.3。

要点

  • 治疗后初始 FDG PET-CT 的汇总敏感度93.3%,特异度57.9%。
  • 手术组 PPV 54.7%,放化疗组31.1%;NPV 分别为100%和96.6%。
  • SUVmax 最佳截断值手术组5.1、放化疗组5.3。

核心结论

  • 手术组治疗后初始 FDG PET-CT 的特异度高于非手术组。
  • 两组中 SUVmax 大于5.0者均应密切评估残留或复发。

研究设计与样本

  • 纳入治疗后1年内接受 PET-CT 者190例,其中103例(54.2%)阳性,61例(32.1%)假阳性。
  • 61例假阳性中42例(68.9%)接受放化疗,19例(31.1%)接受原发手术。
  • 真阳性42例,疾病患病率22.1%。

主要发现

  • 诊断比值比19.3(95%CI 5.7-65.1)。
  • 汇总敏感度93.3%(95%CI 80.7%-98.3%),汇总特异度57.9%(95%CI 49.4%-66.0%)。
  • 手术组 PPV 54.7%(95%CI 38.8%-69.8%),放化疗组31.1%(95%CI 20.2%-44.4%)。
  • 手术组 NPV 100%(95%CI 94.7%-100%),放化疗组96.6%(95%CI 89.5%-99.1%)。
  • 多因素分析显示治疗方式、p16状态和吸烟状态为假阳性指标。

关键数值与推荐

  • 原发肿瘤 ROC 分析:手术组 SUVmax 最佳截断值5.1(AUC 0.729;95%CI 0.570-0.888)。
  • 放化疗组 SUVmax 最佳截断值5.3(AUC 0.844;95%CI 0.700-0.989)。
  • SUVmax 大于5.0者应密切评估残留或复发。

临床怎么用

  • 治疗后初始 FDG PET-CT 阴性预测价值高,尤其手术组 NPV 达100%。
  • 阳性结果需结合治疗方式、p16状态和吸烟状态鉴别假阳性。
  • SUVmax 大于5.0时应警惕残留或复发,建议密切评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: No guidelines at present describe when fludeoxyglucose F 18-labeled positron emission tomography and computed tomography (FDG PET-CT) should be used in the initial posttreatment period for evaluation of oropharyngeal squamous cell carcinoma treatment outcome and recurrence. OBJECTIVE: To compare accuracies of the initial posttreatment PET-CT between primary treatment groups and to define indicators of false-positive findings. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study identified adults with a new diagnosis of oropharyngeal squamous cell carcinoma who received treatment with curative intent from October 1, 2006, through November 30, 2016, using the Alberta Cancer Registry (n = 380). Patients who underwent PET-CT within 1 year of treatment completion were included (n = 190). Of these, 103 patients (54.2%) had PET-CT findings positive for residual or recurrent disease, and 61 (32.1%) had false-positive findings. Among the 61 patients, 42 (68.9%) had received chemoradiotherapy (CRT) and 19 (31.1%) had primary surgery. Forty-two patients had true-positive findings, indicating a prevalence rate of disease of 22.1%. Data were analyzed from July through October 2017. EXPOSURES: One of 2 primary treatment modalities (surgery with or without adjuvant therapy vs CRT). All patients had posttreatment FDG PET-CT. MAIN OUTCOMES AND MEASURES: Primary outcome measures included the diagnostic odds ratio, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PET-CT for detecting residual and/or recurrent disease. A multivariate analysis determined indicators of false-positive findings. Discriminative ability was assessed using receiver operating characteristic curve analysis of maximum standardized uptake value (SUVmax) metabolic data. RESULTS: Of the 190 participants, 77.9% were men, with a mean (SD) age at diagnosis of 58.5 (8.5) years. The diagnostic odds ratio was 19.3 (95% CI, 5.7-65.1); pooled sensitivity, 93.3% (95% CI, 80.7%-98.3%); and pooled specificity, 57.9% (95% CI, 49.4%-66.0%). The PPV of detecting disease was 54.7% (95% CI, 38.8%-69.8%) for primary surgery and 31.1% (95% CI, 20.2%-44.4%) for CRT. The NPV was 100% (95% CI, 94.7%-100%) for primary surgery and 96.6% (95% CI, 89.5%-99.1%) for CRT. Multivariate analysis identified treatment type, p16 disease, and smoking status as indicative of false-positive findings. In the receiver operating characteristic curve analysis for primary tumors, the optimal cutoff SUVmax for indicating true- vs false-positive results was 5.1 for surgically treated patients (area under the curve, 0.729; 95% CI, 0.570-0.888) and 5.3 for patients treated with CRT (area under the curve, 0.844; 95% CI, 0.700-0.989). CONCLUSIONS AND RELEVANCE: The results indicate a higher specificity for FDG PET-CT for initial posttreatment surveillance imaging among patients treated with primary surgery compared with nonsurgical management. Both sets of patients with posttreatment FDG PET-CT findings with an SUVmax greater than 5.0 should undergo close evaluation for possible residual or recurrent disease.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Sivarajah S, Isaac A, Cooper T, et al. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 30242338. doi:10.1001/jamaoto.2018.2143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。